丙氨酰谷氨酰胺补充透析液对腹膜健康生物标志物的随机对照试验
这项双盲随机交叉试验在稳定腹膜透析患者中评估了在透析液中添加丙氨酰谷氨酰胺(AlaGln,8 mM)8周对腹膜健康生物标志物的影响。结果显示AlaGln显著提高透析液CA-125出现率和离体刺激IL-6释放,并减少腹膜蛋白丢失、增加TNF-α释放、降低全身IL-8水平,无安全信号。
要点
- AlaGln补充透析液可改善腹膜间皮细胞质量和免疫应答的生物标志物。
- AlaGln补充可减少腹膜蛋白丢失并降低全身炎症标志物IL-8。
- 所有腹膜炎事件均发生在标准透析液治疗期间,未观察到安全信号。
核心结论
- 新型AlaGln补充透析液相比未补充的中性pH低葡萄糖降解产物透析液,可改善腹膜膜完整性、免疫能力和全身炎症的生物标志物。
研究设计与样本
- 双盲随机交叉设计,稳定腹膜透析患者接受AlaGln(8 mM)或安慰剂添加至透析液治疗8周。
- 在8个奥地利中心筛选54例,随机50例,41例纳入全分析集。
主要发现
- AlaGln补充显著增加透析液CA-125出现率和离体刺激IL-6释放。
- AlaGln补充减少腹膜蛋白丢失、增加离体刺激TNF-α释放、降低全身IL-8水平。
- 未观察到不良安全信号,所有4例腹膜炎均发生在标准透析液治疗期间。
关键数值与推荐
- 主要结局指标为腹膜平衡试验中透析液CA-125出现率和离体刺激IL-6释放。
- AlaGln浓度为8 mM,治疗持续8周。
临床怎么用
- 对于稳定腹膜透析患者,使用AlaGln补充透析液可能改善腹膜健康相关生物标志物。
- 需等待3期试验确定AlaGln补充对硬临床结局的影响后再广泛推荐。
局限性
- 样本量较小(全分析集41例),随访8周,主要结局为生物标志物而非硬临床结局。
- 需要3期试验确定对硬临床结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In early clinical testing, acute addition of alanyl-glutamine (AlaGln) to glucose-based peritoneal dialysis (PD) fluids restored peritoneal cellular stress responses and leukocyte function. This study was designed to test the effect of extended treatment with AlaGln-supplemented PD fluid on biomarkers of peritoneal health. In a double-blinded, randomized crossover design, stable PD patients were treated with AlaGln (8 mM) or placebo added to PD fluid for eight weeks. As primary outcome measures, dialysate cancer-antigen 125 (CA-125) appearance rate and ex vivo stimulated interleukin-6 (IL-6) release were assessed in peritoneal equilibration tests. In 8 Austrian centers, 54 patients were screened, 50 randomized, and 41 included in the full analysis set. AlaGln supplementation significantly increased CA-125 appearance rate and ex vivo stimulated IL-6 release. AlaGln supplementation also reduced peritoneal protein loss, increased ex vivo stimulated tumor necrosis factor (TNF)-α release, and reduced systemic IL-8 levels. No adverse safety signals were observed. All 4 peritonitis episodes occurred during standard PD fluid treatment. A novel AlaGln-supplemented PD fluid improves biomarkers of peritoneal membrane integrity, immune competence, and systemic inflammation compared to unsupplemented PD fluid with neutral pH and low-glucose degradation. A phase 3 trial is needed to determine the impact of AlaGln supplementation on hard clinical outcomes.
引用
- Vychytil A, Herzog R, Probst P, et al. A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. Kidney Int. 2018. PMID: 30360960. doi:10.1016/j.kint.2018.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。